Platelet inhibition with prasugrel (CS‐747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study

BACKGROUND: Based on the preclinical and phase 1 studies, prasugrel, a novel platelet ADP P2Y12 receptor blocker, may be a more potent platelet inhibitor than clopidogrel. This study compared the antiplatelet properties of prasugrel in a small subset of patients enrolled in the JUMBO trial, and comp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Serebruany, V L, Midei, M G, Meilman, H, Malinin, A I, Lowry, D R
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Group 2006
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2563744/
https://ncbi.nlm.nih.gov/pubmed/16754711
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/pgmj.2006.047696
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados